Sign in
CompletedPhase 4

A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults

Key facts

Who runs it
Tor Biering-Sørensen
Where
Denmark2 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 4
People taking part
332,438 people enrolled
Started
22 Sept 2022
Ended
31 Aug 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • High-Dose Quadrivalent Influenza Vaccine
  • Standard-Dose Quadrivalent Influenza Vaccine
Record updated
12 September 2025

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Age 65 years and above (this inclusion criterion will be modified according to the Danish government's official recommendations for the 2022/2023 and 2023/2024 influenza seasons)
  • Informed consent form has been signed and dated

Who cannot take part

  • There are no specific exclusion criteria for this study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this pragmatic randomized trial is to evaluate the relative vaccine effectiveness of high-dose quadrivalent influenza vaccine (QIV-HD) vs. standard-dose quadrivalent influenza vaccine (QIV-SD) in older adults. Participants will be randomized 1:1 to either QIV-HD or QIV-SD.

The 2 groups in the trial

  • High-Dose Quadrivalent Influenza VaccineTreatment being tested

    QIV-HD single injection at Day 0

  • Standard-Dose Quadrivalent Influenza VaccineExisting treatment, for comparison

    QIV-SD single injection at Day 0

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Publications
Record updated
12 September 2025